Trials / Completed
CompletedNCT01306110
Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 277 (actual)
- Sponsor
- Association HGE CHU Bordeaux Sud · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.
Detailed description
Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.
Conditions
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2011-03-01
- Last updated
- 2016-01-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01306110. Inclusion in this directory is not an endorsement.